JP6640715B2 - 腫瘍毒性に対する標的コロールおよびmri - Google Patents
腫瘍毒性に対する標的コロールおよびmri Download PDFInfo
- Publication number
- JP6640715B2 JP6640715B2 JP2016513057A JP2016513057A JP6640715B2 JP 6640715 B2 JP6640715 B2 JP 6640715B2 JP 2016513057 A JP2016513057 A JP 2016513057A JP 2016513057 A JP2016513057 A JP 2016513057A JP 6640715 B2 JP6640715 B2 JP 6640715B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- corrole
- tumor
- nanoparticles
- target
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本出願は、2013年5月8日に出願された米国仮出願第61/821,106号に対する優先権を主張し、図面を含むその全開示は本明細書に参照により組み込まれる。
米国政府は、本発明において支払い済みのライセンスを有し、国立衛生研究所によって承認されている認可番号CA129822およびCA140995ならびに国立先進トランスレーショナルサイエンスセンターによって承認されている認可番号UL1TR000124によって与えられているように妥当な条件で特許権者が他者とライセンスすることを必要とする限定された状況において権利を有する。
本発明は、癌の治療および画像化技術に関する。
Mn−コロールはインビトロにおいて最も高いT1緩和時間を示す。
本発明者らは、コロールの初期パネルを評価して、もしあれば、MRIについての造影剤としての可能性を示すかどうかを判定した。このことを判定するために、本発明者らは、インビトロでの条件下で増加させていった濃度の各々についてT1時間減少を測定した。測定した3つのコロール(ガリウム、鉄、およびマンガン−メタル化化合物)のうち、Mnコロール、S2Mnが最も大きなT1時間短縮を示した(図1)。したがって後の研究はこの化合物を使用して実施した。
標的Mn−コロール、HerMnはインビボで腫瘍を死滅させる。
本発明者らは、S2Mnが、標的タンパク質、HerPBK10によって送達される場合、腫瘍に対して毒性があるかどうかを試験した。S2MnとHerPBK10(HerMnと呼ばれる;図2)との間の非共有結合相互作用から生じる粒子を、ヒトHER2+癌のインビボ異種移植マウスモデルにおいて腫瘍標的毒性について試験した。本発明者らは、7日間毎日、尾静脈注射により、1回の注射あたり5nmolのHerMnまたは等価量のS2Mn単独、HerPBK10単独、および生理食塩水を送達し、最後の注射後、25日間腫瘍成長についてモニターした。この研究は、HerMnがインビボで腫瘍成長減少を引き起こしたが、個々の構成成分では引き起こさなかったことを示した(図3)。
S2MnはインビボでT1時間短縮およびMRIコントラストを示す。
S2MnがMRIによるコントラストを示すかどうかを決定するために、本発明者らは、異なる用量/注射での腫瘍内注射の後、インビボでS2MnのT1時間短縮を測定した。腫瘍内の100umoleのS2Mn蓄積は、対側の腫瘍内に注射される等しい量の生理食塩水と比較してT1時間短縮の有意な差を生じた(図4A)。しかしながら、1mmoleのS2Mnはバックグラウンド組織シグナルから良好に識別できる良好なT1時間減少を生じ(図4A)、同様にMRIによって検出可能なコントラストを生じた(図4B)。
概説
本明細書に開示されるように、本発明者らは、同時に腫瘍検出および治療を可能にする腫瘍標的タンパク質ベースのナノ粒子を開発した。一実施形態において、ナノ粒子は、水溶性スルホン化コロールとの組換え腫瘍標的細胞透過タンパク質(HerPBK10)の非共有結合によって形成され、10〜20nm直径の球形のウイルス様粒子を生じる。HerPBK10は腫瘍標的および細胞膜透過を容易にするのに対して、コロールはタンパク質に非共有結合し、検出および細胞毒性を可能にする。本発明者らは、HerPBK10によるガリウムメタル化コロールの送達(複合体、HerGaを生じる)が、Her2+腫瘍を選択的に殺傷しながら、腫瘍標的を追跡するための強い赤色蛍光を発することができることを実証した。しかしながら、HerGaを使用する腫瘍検出は、腫瘍が皮膚の下、数センチメートル内に局在化する場合のみ可能である。なぜなら、光の侵入深さは数セントメートルに制限されるからである。したがって、臨床における腫瘍検出のためのHerGaの使用は、内視鏡技術を含む、より高度な画像化法を必要とし得る。本明細書に開示されるように、本発明者らは、HerPBK10と組み合わされる場合、HerGaと同じ細胞毒性であるが、MRIなどの臨床に関連する装置を使用した検出を可能にする十分なコントラスト特性を有する代替のメタル化コロールが使用され得るかどうかを調べた。本発明者らは、マンガン(Mn)および鉄(Fe)コロール(それぞれHerMnまたはHerFe)を有する腫瘍標的粒子が、インビボでHER2+腫瘍細胞に対する標的毒性を維持しながらMRIについての十分なコントラストを有するかどうかを試験した。
Claims (13)
- 標的ポリペプチドとコロールとを含む標的ナノ粒子を含む組成物であって、前記コロールはマンガン(Mn)を含み、
前記標的ポリペプチドはHER2+腫瘍細胞を標的とする、
対象における癌の治療に使用するための組成物。 - 前記標的ポリペプチドは腫瘍標的ポリペプチドである、請求項1に記載の組成物。
- 対象における状態を画像化するのに使用するための請求項1または2に記載の組成物。
- 標的ポリペプチドとコロールとを含む標的ナノ粒子を含む組成物であって、前記コロールはマンガン(Mn)を含む、対象における状態を磁気共鳴画像法(MRI)によって画像化するのに使用するための組成物。
- 前記標的ポリペプチドはHER2+腫瘍細胞を標的とする、請求項4に記載の組成物。
- 前記状態は癌である、請求項3または4に記載の組成物。
- 前記画像化は磁気共鳴画像法(MRI)による、請求項3に記載の組成物。
- 前記コロールはスルホン化される、請求項1〜7のいずれか一項に記載の組成物。
- 前記コロールはS2Mnである、請求項1〜8のいずれか一項に記載の組成物。
- 前記標的ポリペプチドはHerPBK10分子である、請求項1〜9のいずれか一項に記載の組成物。
- 前記組成物は、エアロゾル、経鼻、経口、経粘膜、経皮、静脈内または非経口投与用に製剤化される、請求項1〜10のいずれか一項に記載の組成物。
- 前記組成物は非経口投与用に製剤化される、請求項11に記載の組成物。
- 前記組成物は静脈投与用に製剤化される、請求項12に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361821106P | 2013-05-08 | 2013-05-08 | |
US61/821,106 | 2013-05-08 | ||
PCT/US2014/037234 WO2014182868A1 (en) | 2013-05-08 | 2014-05-08 | Targeting corroles for tumor toxicity and mri |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016526021A JP2016526021A (ja) | 2016-09-01 |
JP2016526021A5 JP2016526021A5 (ja) | 2017-06-22 |
JP6640715B2 true JP6640715B2 (ja) | 2020-02-05 |
Family
ID=51864925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016513057A Expired - Fee Related JP6640715B2 (ja) | 2013-05-08 | 2014-05-08 | 腫瘍毒性に対する標的コロールおよびmri |
Country Status (17)
Country | Link |
---|---|
US (2) | US9757386B2 (ja) |
EP (2) | EP2993983B1 (ja) |
JP (1) | JP6640715B2 (ja) |
KR (1) | KR20160008523A (ja) |
CN (2) | CN108451930A (ja) |
AU (2) | AU2014262653B2 (ja) |
CA (1) | CA2910030A1 (ja) |
DK (1) | DK2993983T3 (ja) |
ES (1) | ES2791043T3 (ja) |
HK (1) | HK1221870A1 (ja) |
IL (1) | IL265935B (ja) |
MX (1) | MX2015015434A (ja) |
PL (1) | PL2993983T3 (ja) |
PT (1) | PT2993983T (ja) |
RU (1) | RU2674146C2 (ja) |
WO (1) | WO2014182868A1 (ja) |
ZA (1) | ZA201508092B (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009009441A2 (en) | 2007-07-06 | 2009-01-15 | Cedars-Sinai Medical Center | Self-assembling complex for targeting chemical agents to cells |
WO2010085665A2 (en) | 2009-01-23 | 2010-07-29 | Cedars-Sinai Medical Center | Targeted delivery system |
PL2880160T3 (pl) | 2012-08-03 | 2019-03-29 | Cedars-Sinai Medical Center | Izolowanie wzmacniających transport mutantów białka dostarczającego lek |
US9757386B2 (en) | 2013-05-08 | 2017-09-12 | Cedars-Sinai Medical Center | Targeting corroles for tumor toxicity and MRI |
MX2016009284A (es) | 2014-01-17 | 2016-10-07 | Cedars Sinai Medical Center | Construcciones dirigidas a receptor y sus usos. |
US9850293B2 (en) | 2014-04-04 | 2017-12-26 | Cedars-Sinai Medical Center | Targeting trastuzumab-resistant HER2+ breast cancer with a HER3-targeting nanoparticle |
EP3687998A4 (en) * | 2017-08-31 | 2021-05-19 | Technion Research & Development Foundation Limited | CORROL COMPOSITIONS |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA129822A (en) | 1910-08-24 | 1910-12-13 | The John Bertram And Sons Company, Limited | Motor controlling apparatus |
CA140995A (en) | 1912-03-05 | 1912-06-11 | Davydd C. Hughes | Type plate mechanism |
US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
WO2002094318A1 (en) | 2001-05-18 | 2002-11-28 | University Of Southern California | Vector for targeted delivery to cells |
WO2003004021A1 (en) * | 2001-07-02 | 2003-01-16 | Technion Research And Development Foundation Ltd. | Method for the preparation of selectively-substituted corroles and new substituted corroles |
US8080534B2 (en) | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
WO2009009441A2 (en) | 2007-07-06 | 2009-01-15 | Cedars-Sinai Medical Center | Self-assembling complex for targeting chemical agents to cells |
AU2008293376B2 (en) | 2007-08-28 | 2013-07-11 | Technion Research & Development Foundation Ltd. | Transition metal complexes of corroles for preventing cardiovascular diseases or disorders |
CA2751058A1 (en) * | 2008-01-31 | 2009-08-06 | Technion Research And Development Foundation Ltd | Corroles for neuroprotection and neurorescue |
WO2009151539A1 (en) | 2008-05-24 | 2009-12-17 | Sirnaomics, Inc. | COMPOSITIONS AND METHODS USING siRNA MOLECULES FOR TREATMENT OF GLIOMAS |
WO2010078517A2 (en) | 2008-12-31 | 2010-07-08 | Sirnaomics, Inc. | Compositions and methods using sirna molecules and sirna cocktails for the treatment of breast cancer |
WO2010085665A2 (en) | 2009-01-23 | 2010-07-29 | Cedars-Sinai Medical Center | Targeted delivery system |
CN101704820A (zh) * | 2009-09-24 | 2010-05-12 | 江苏大学 | 三(4-氯苯基)咔咯化合物及其合成方法 |
WO2011094335A2 (en) | 2010-01-26 | 2011-08-04 | Yale University | Microrna signatures predicting responsiveness to anti-her2 therapy |
MX2014001823A (es) * | 2011-08-15 | 2014-08-21 | Technion Res & Dev Foundation | Combinaciones de corroles y estatinas. |
PL2880160T3 (pl) | 2012-08-03 | 2019-03-29 | Cedars-Sinai Medical Center | Izolowanie wzmacniających transport mutantów białka dostarczającego lek |
US9757386B2 (en) | 2013-05-08 | 2017-09-12 | Cedars-Sinai Medical Center | Targeting corroles for tumor toxicity and MRI |
MX2016009284A (es) | 2014-01-17 | 2016-10-07 | Cedars Sinai Medical Center | Construcciones dirigidas a receptor y sus usos. |
US9850293B2 (en) | 2014-04-04 | 2017-12-26 | Cedars-Sinai Medical Center | Targeting trastuzumab-resistant HER2+ breast cancer with a HER3-targeting nanoparticle |
KR20190013929A (ko) | 2016-05-27 | 2019-02-11 | 세다르스-신나이 메디칼 센터 | 약물-전달 나노입자 및 약물 내성암에 대한 치료 |
-
2014
- 2014-05-08 US US14/272,610 patent/US9757386B2/en active Active
- 2014-05-08 CN CN201810246983.5A patent/CN108451930A/zh not_active Withdrawn
- 2014-05-08 CN CN201480025009.6A patent/CN105307499B/zh not_active Expired - Fee Related
- 2014-05-08 KR KR1020157030349A patent/KR20160008523A/ko not_active Application Discontinuation
- 2014-05-08 AU AU2014262653A patent/AU2014262653B2/en not_active Ceased
- 2014-05-08 MX MX2015015434A patent/MX2015015434A/es unknown
- 2014-05-08 EP EP14794410.2A patent/EP2993983B1/en active Active
- 2014-05-08 WO PCT/US2014/037234 patent/WO2014182868A1/en active Application Filing
- 2014-05-08 EP EP20157304.5A patent/EP3730155A1/en not_active Withdrawn
- 2014-05-08 RU RU2015152033A patent/RU2674146C2/ru active
- 2014-05-08 PT PT147944102T patent/PT2993983T/pt unknown
- 2014-05-08 PL PL14794410T patent/PL2993983T3/pl unknown
- 2014-05-08 JP JP2016513057A patent/JP6640715B2/ja not_active Expired - Fee Related
- 2014-05-08 ES ES14794410T patent/ES2791043T3/es active Active
- 2014-05-08 CA CA2910030A patent/CA2910030A1/en not_active Abandoned
- 2014-05-08 DK DK14794410.2T patent/DK2993983T3/da active
-
2015
- 2015-11-02 ZA ZA2015/08092A patent/ZA201508092B/en unknown
-
2016
- 2016-08-25 HK HK16110127.7A patent/HK1221870A1/zh unknown
-
2017
- 2017-06-15 US US15/624,228 patent/US10709801B2/en active Active
-
2018
- 2018-10-17 AU AU2018250401A patent/AU2018250401B2/en not_active Ceased
-
2019
- 2019-04-10 IL IL265935A patent/IL265935B/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
RU2674146C2 (ru) | 2018-12-07 |
HK1221870A1 (zh) | 2017-06-16 |
ZA201508092B (en) | 2017-02-22 |
AU2014262653B2 (en) | 2018-07-26 |
PT2993983T (pt) | 2020-05-22 |
JP2016526021A (ja) | 2016-09-01 |
DK2993983T3 (da) | 2020-05-18 |
US20140335025A1 (en) | 2014-11-13 |
AU2014262653A1 (en) | 2015-11-12 |
WO2014182868A1 (en) | 2014-11-13 |
IL265935A (en) | 2019-05-30 |
CN105307499A (zh) | 2016-02-03 |
RU2015152033A3 (ja) | 2018-04-25 |
CA2910030A1 (en) | 2014-11-13 |
CN108451930A (zh) | 2018-08-28 |
IL265935B (en) | 2020-06-30 |
EP2993983A1 (en) | 2016-03-16 |
US10709801B2 (en) | 2020-07-14 |
EP3730155A1 (en) | 2020-10-28 |
MX2015015434A (es) | 2016-03-15 |
US20170281802A1 (en) | 2017-10-05 |
EP2993983B1 (en) | 2020-03-25 |
EP2993983A4 (en) | 2017-01-11 |
AU2018250401A1 (en) | 2018-11-08 |
PL2993983T3 (pl) | 2020-09-07 |
CN105307499B (zh) | 2018-04-27 |
AU2018250401B2 (en) | 2020-06-11 |
ES2791043T3 (es) | 2020-10-30 |
KR20160008523A (ko) | 2016-01-22 |
RU2015152033A (ru) | 2017-06-16 |
US9757386B2 (en) | 2017-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6640715B2 (ja) | 腫瘍毒性に対する標的コロールおよびmri | |
Song et al. | Liposomes co-loaded with metformin and chlorin e6 modulate tumor hypoxia during enhanced photodynamic therapy | |
Jiang et al. | Combating multidrug resistance and metastasis of breast cancer by endoplasmic reticulum stress and cell-nucleus penetration enhanced immunochemotherapy | |
Liu et al. | Non-invasive sensitive brain tumor detection using dual-modality bioimaging nanoprobe | |
US20230390394A1 (en) | Bismuth-Gadolinium Nanoparticles | |
Wang et al. | Self-assembly of photosensitive and radiotherapeutic peptide for combined photodynamic-radio cancer therapy with intracellular delivery of miRNA-139-5p | |
Jo et al. | Recent trend of ultrasound-mediated nanoparticle delivery for brain imaging and treatment | |
Prakash et al. | NLRP3 inflammasome-targeting nanomicelles for preventing ischemia–reperfusion-induced inflammatory injury | |
Wang et al. | Novel bone tumor cell targeting nanosystem for chemo-photothermal therapy of malignant bone tumors | |
Han et al. | Spatiotemporal tracking of gold nanorods after intranasal administration for brain targeting | |
Li et al. | Melanin-gelatin nanoparticles with both EPR effect and renal clearance for PA/MRI dual-modal imaging of tumors | |
Hasan et al. | Parkinson's Disease: Current Status, Diagnosis, and Treatment Using Nanomedicines | |
CN113993554A (zh) | 选自食道、咽喉、肺、脑和肠的癌症的靶向化合物 | |
CN114788862B (zh) | 一种锰基放疗增敏剂及其制备方法和应用 | |
Divband et al. | Fe3O4/graphene-based nanotheranostics for bimodal magnetic resonance/fluorescence imaging and cancer therapy | |
CN117677405A (zh) | 具有较高吸收率的靶向系统 | |
Jia et al. | Radioiodine‐131‐Labeled Theranostic Nanoparticles for Transarterial Radioembolization and Chemoembolization Combination Therapy of VX2 Liver Tumor | |
Sarfaraz et al. | Nanotechnology and it’s therapeutic application-a review | |
US20210268129A1 (en) | Theranostic Radiophotodynamic Therapy Nanoparticles | |
Abdelhamid | Metal-organic frameworks (MOFs) as a unique theranostic nanoplatforms for therapy and imaging | |
CN111973761A (zh) | 一种具有肿瘤诊疗功能的外泌体及其制备方法与应用 | |
Zoey et al. | Multifunctional Nanoparticles and Nanoclusters as a Theranostics and Symptoms Disappearing Agent for Traumatic Brain Injury | |
US20240016850A1 (en) | Cell-nanoparticle drug delivery system and use of the same for inhibiting growth of tumor cells and diagnosing tumor cells | |
Al-Khater et al. | Application of Nanomaterials in Treatment of Endocrine Diseases | |
Xu et al. | Tumor microenvironment responsive nano-platform for overcoming sorafenib resistance of hepatocellular carcinoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170508 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170508 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180130 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180425 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180626 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180627 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181204 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190213 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190716 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191015 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191210 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191226 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6640715 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |